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Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder characterized by
smooth-muscle tumors of the skin and uterus and/or renal cancer. Although the identification of germline mutations
in the fumarate hydratase (FH) gene in European families supports it as the susceptibility gene for HLRCC, its
role in families in North America has not been studied. We screened for germline mutations in FH in 35 families
with cutaneous leiomyomas. Sequence analysis revealed mutations in FH in 31 families (89%). Twenty different
mutations in FH were identified, of which 18 were novel. Of these 20 mutations, 2 were insertions, 5 were small
deletions that caused frameshifts leading to premature truncation of the protein, and 13 were missense mutations.
Eleven unrelated families shared a common mutation: R190H. Eighty-one individuals (47 women and 34 men)
had cutaneous leiomyomas. Ninety-eight percent (46/47) of women with cutaneous leiomyomas also had uterine
leiomyomas. Eighty-nine percent (41/46) of women with cutaneous and uterine leiomyomas had a total hyster-
ectomy, 44% at age 30 years. We identified 13 individuals in 5 families with unilateral and solitary renal tumors.
Seven individuals from four families had papillary type II renal cell carcinoma, and another individual from one
of these families had collecting duct carcinoma of the kidney. The present study shows that mutations in FH are
associated with HLRCC in North America. HLRCC is associated with clinically significant uterine fibroids and
aggressive renal tumors. The present study also expands the histologic spectrum of renal tumors and FH mutations
associated with HLRCC.
Introduction
Uterine leiomyomas (fibroids) are the most common gy-
necological tumors in women of reproductive age, with
prevalence ranging from 20% to 77% (Cramer and Pa-
tel 1990; Stewart 2001). Their presence is the most com-
mon indication for hysterectomy in women in the United
States (Stewart 2001; Farquhar and Steiner 2002). His-
torically, the autosomal dominant predisposition to the
development of leiomyomas of the skin was referred to
as “multiple cutaneous leiomyomatosis” (MIM 150800).
Cutaneous leiomyomas are benign smooth-muscle tu-
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mors, typically with onset during early adulthood. Cu-
taneous leiomyomas have been associated with renal
carcinomas, uterine leiomyomas, and leiomyosarcomas
(Reed et al. 1973; Launonen et al. 2001). In 1973, Reed
et al. (1973) described two kindreds in which multiple
members, over three generations, exhibited cutaneous
leiomyomas, uterine leiomyomas, and/or leiomyosarco-
mas inherited in an autosomal dominant pattern. The
association between cutaneous and uterine leiomyomas
is known as “Reed syndrome.”
Recently, Launonen et al. (2001) described a new
familial renal cancer syndrome named “hereditary lei-
omyomatosis and renal cell cancer” (HLRCC [MIM
605839]). They described two kindreds in which cuta-
neous and uterine leiomyomas and papillary type II
renal cell carcinoma segregated together, and, using a
genomewide scan, they mapped the HLRCC locus to
a region on 1q42-44. Subsequently, an independent
group narrowed the leiomyoma locus to a 14-cM re-
gion on 1q42.3-43 (Alam et al. 2001). More recently,
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in collaboration, these groups reported that germline
mutations in the FH gene—encoding fumarate hydra-
tase (FH), an enzyme that catalyzes the conversion of
fumarate to malate in the Krebs cycle—predispose to
dominantly inherited uterine fibroids, skin leiomyoma,
and papillary type II renal cell cancer (Tomlinson et
al. 2002). These mutations are predicted to result in
absent or truncated protein or in substitutions or de-
letions of highly conserved amino acids. FHmost likely
acts as a tumor suppressor in HLRCC, since loss of
heterozygosity (LOH) studies showed loss of the wild-
type allele in cutaneous, uterine, and renal tumors and
since the enzyme activity of FH is low or absent in
tumors from individuals with leiomyomas (Tomlinson
et al. 2002).
Mutations in FH also occur in fumarate hydratase defi-
ciency (FHD [MIM 136850]). Homozygous/compound-
heterozygous FH germline mutations cause autosomal
recessive FHD, which is characterized by neurological
impairment and encephalopathy (Gellera at al. 1990;
Bourgeron et al. 1994; Coughlin et al. 1998). Mamma-
lian tissues contain two FH isoenzymes: cytosolic and
mitochondrial (Edwards and Hopkinson 1979; Sass et
al. 2001). A noticeable exception is the brain, in which
only the mitochondrial isoenzymes have been identified
(Akiba et al. 1984; Bourgeron et al. 1994). This may
explain why FHD predominantly affects brain function.
In 1996, we encountered a family with cutaneous
and uterine leiomyomas and papillary renal cancer in-
herited in an autosomal dominant fashion. The renal
tumors had a unique histology, different from classic
papillary type I renal cell carcinoma seen in hereditary
papillary renal cell carcinoma (HPRC) (Schmidt et al.
1997). In addition, this family’s disease phenotype,
now known as “HLRCC,” was not linked to 7q31,
and no germline mutations were found in the tyrosine
kinase domain of the MET proto-oncogene (unpub-
lished data). To recruit patients in an effort to map
and identify the HLRCC-susceptibility gene, we sent
two cycles of letters to 11,000 dermatologists through-
out the United States and Canada. Similar to previous
reports (Alam et al. 2001; Launonen et al. 2001), stud-
ies in our laboratory showed that the HLRCC-suscep-
tibility gene maps to 1q42.3, the locus for FH. Sub-
sequently, we screened a cohort of families in North
America with HLRCC for mutations in FH. We also
recruited patients to investigate the health problems
associated with cutaneous leiomyomas, particularly
focusing on renal tumors and uterine fibroids. We in-
vestigated whether inheritance of germline mutations
in FH predisposed individuals in these families to the
development of renal tumors or uterine fibroids.
Patients and Methods
Patient Recruitment
We recruited family members with cutaneous leiomy-
omas by mailing, over a 2-year period, two cycles of
∼22,000 patient-recruitment letters to members of the
American Academy of Dermatology. All families were
invited to participate in the study regardless of the num-
ber of affected individuals in the family and regardless
of the presence or absence of associated health prob-
lems (renal tumors or uterine fibroids). Subjects were
evaluated in consecutive order. An additional three fam-
ilies with HLRCC, which were previously examined in
the Clinical Center, were included in the study. The pro-
tocol was approved by the institutional review board of
the National Cancer Institute. All members of families
screened for HLRCC who participated in the present
study gave written informed consent.
Patient Evaluation
Families with cutaneous leiomyomas were evaluated at
the Clinical Center of the National Institutes of Health
and on field trips. Patients were interviewed for a history
of cutaneous leiomyomas, uterine fibroids, hysterecto-
mies, and renal tumors. Each patient had a detailed ex-
amination (by M.L.T. or J.R.T.) of the skin, including
biopsies of selected lesions suspected to be leiomyomas.
For the detection of occult malignancies, family mem-
bers who came to the National Institutes of Health Clini-
cal Center were examined by computed tomography (CT)
scans of the chest, abdomen, and pelvis, followed by renal
ultrasound. The kidneys were scanned before and after
administration of ∼120 cc Ioxilan 300 (Cook Imaging).
High-resolution (1-mm) sections were obtained through
the chest, at 10-mm intervals. Renal ultrasound was per-
formed with 3–5-MHz gray-scale and color Doppler
transducers with one of two units (Acuson Sequoia or
ATL HDI 8000). Women who still had a uterus under-
went magnetic resonance imaging (MRI) of the pelvis.
Because patients with FHD typically present with severe
neurological impairment, we evaluated the present co-
hort of patients for neurological signs and symptoms.
Definitions
We defined an individual as affected with HLRCC
if that individual showed 110 skin lesions clinically
compatible with leiomyoma and a minimum of 1 le-
sion histologically confirmed as a leiomyoma. Histo-
logically, leiomyomas were a proliferation of interlac-
ing bundles of smooth-muscle fibers with a centrally
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located long blunt-edged nucleus. We defined a family
as affected with HLRCC if it contained one or more
members affected with cutaneous leiomyomas. Renal
tumors were diagnosed on the basis of histologic ex-
amination of resected tumors or on the basis of CT
scans and renal ultrasound. Renal lesions 11 cm in
diameter with 110 Hounsfield units of enhancement
that were not cystic on ultrasound were considered
to be renal tumors. Uterine fibroids were document-
ed by history, review of medical records, physical ex-
amination, MRI, and CT. Hysterectomy was docu-
mented by history and a review of medical records,
as well as by absence of the uterus on CT scan.
Statistical Analysis
A paired Student’s t test was performed to determine
whether there was a difference between the mean age at
onset of cutaneous leiomyomas and the mean age at diag-
nosis of uterine fibroids. All analyses were done on SPSS,
version 10.1.4. The possible relationship between renal
cancer occurrence and the location of a mutation was
assessed using Fisher’s exact test.
Haplotype Analysis
DNA was extracted from peripheral blood or buccal
swabs according to standard procedures. Primer sets
for microsatellite markers (D1S517, D1S304, D1S180,
D1S404, D1S1609, and D1S2836) around the HLRCC
locus, at 1q42.3-43, were purchased from Research Ge-
netics. Microsatellite genotyping and haplotype analysis
were performed as described elsewhere (Schmidt et al.
2001). Haplotypes were constructed from the genotypes
of these six polymorphic microsatellite markers, to iden-
tify alleles that were consistently inherited with cutane-
ous leiomyomas. Haplotypes were generated under the
assumption that the smallest numbers of recombinations
were present.
Sequencing of the FH Gene
DNA was extracted from peripheral blood leukocytes
or buccal swabs according to standard procedures. The
genomic sequence that contained FH was determined by
BLAST alignment of the mitochondrial FH precursor
cDNA (GenBank accession number U59309) with the
BAC genomic sequences (GenBank accession numbers
AL359764 and AL591898). Primers and PCR conditions
are available on request. Supplemental experimental pro-
cedures—including methods for identification of exon-
intron boundaries, high-throughput DNA sequencing,
and analysis—are described in appendix A.
Results
Patient Description
Eighty-one individuals from 35 families exhibited cu-
taneous leiomyomas. There were 47 women and 34men,
ranging from 22 to 90 years of age. An additional 14
individuals were FH-mutation carriers; of these individ-
uals, the skin status of 6 was unknown, and 8 lacked
cutaneous leiomyomas after a detailed skin examination.
Cutaneous Leiomyomas
Clinically, cutaneous leiomyomas presented as firm,
skin-colored to light-brown-colored papules and nod-
ules (fig. 1). One individual had a cutaneous leiomyo-
sarcoma. The number of lesions ranged from 10 to 1100,
and the size ranged from 0.4 to 2.5 cm in diameter. An
exception was seen in a 22-year-old woman in whom
detailed skin examination revealed a single leiomyoma;
however, her brother and her father exhibited multiple
cutaneous leiomyomas. Patients stated that the number
of cutaneous lesions increased with time. Lesions were
mostly distributed over the trunk and extremities, except
for two patients who also developed multiple lesions on
their faces. There were two patterns of cutaneous in-
volvement: disseminated and a combination of dissem-
inated and segmental distribution. Of individuals with
cutaneous leiomyomas, 92% complained of pain and
paresthesias associated with the cutaneous lesions. As
shown in figure 2, the reported onset of cutaneous leio-
myomas ranged from 10 to 47 years of age ( ),np 79
with a mean age at onset of 25 years.
Uterine Fibroids and Related Gynecological Surgeries
Ninety-eight percent (46/47) of women with cutaneous
leiomyomas had uterine leiomyomas (fibroids). Uterine
fibroids were numerous and large, ranging from 1 to 20
tumors and from 1.5 to 10 cm in diameter, respectively.
Patients complained of early onset of fibroid-associated
symptoms, including irregular menses, menorrhagia, and
pain. Ninety-one percent (42/46) of women with cutane-
ous and uterine leiomyomas underwent a myomectomy
or hysterectomy to treat fibroids. Of these 42 women, 41
underwent a hysterectomy, and 1 had a myomectomy at
age 27 years. Fifty-seven percent of women with cutane-
ous and uterine leiomyomas had a hysterectomy at 30
years of age. Although review of hysterectomy pathology
reports did not reveal any uterine leiomyosarcomas, two
women had uterine fibroids, with severe atypia in one and
mild atypia in the other.
Eight women without a history of a hysterectomywere
screenedwithMRI of the pelvis, for the detection of occult
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Figure 1 Clinical, histologic, and radiologic manifestations of HLRCC. A, Segmental distribution of leiomyomas in a 32-year-old man.
Clinically, cutaneous leiomyomas presented as firm skin-colored to light-brown-colored papules and nodules. B,Histology of cutaneous leiomyoma.
Leiomyomas were a proliferation of interlacing bundles of smooth-muscle fibers with a centrally located long blunt-edged nucleus in the dermis.
C, Abdominal CT scan, showing the location of a renal tumor in the 32-year-old man shown in panel A. The resected neoplasm was a papillary
type II renal cell carcinoma, as shown in panel D. D, Histologic findings of papillary type II renal cell carcinoma. There is a distinct papillary
architecture. Cells had an abundant amphophilic cytoplasm and large nuclei with large inclusion-like eosinophilic nucleoli. Magnification# 200.
uterine fibroids. Of these eight women, seven had uterine
fibroids (five had cutaneous leiomyomas and FH muta-
tions, and two were FH-mutation carriers).
To investigate the clinical presentation of the disease,
we plotted the ages at onset of cutaneous leiomyomas
and the ages at diagnosis of uterine fibroids. The age at
diagnosis of uterine fibroids ranged from 18 to 52 years,
with a mean age at diagnosis of 30 years. Cutaneous
leiomyomas occurred at a marginally statistically sig-
nificant ( ) earlier mean age (25 years), in com-Pp .048
parison with the mean age at diagnosis of uterine fibroids
(30 years) (fig. 2).
Uterine fibroids also occurred in 10 women who were
FH-mutation carriers. Of these 10 women, 3 did not
have cutaneous leiomyomas after a meticulous skin ex-
amination, and 7 were deceased (thus, their skin status
is unknown). Three other women who were FH-muta-
tion carriers (respectively, 24, 25, and 28 years of age)
did not have uterine fibroids after pelvic MRI exami-
nation; however, these three women are young and are
still at risk for the development of cutaneous and uterine
leiomyomas.
Renal Tumors
Thirteen members (five men and eight women) from
five families were affected with renal cell carcinoma. In
nine cases, pathological confirmation of the diagnosis
was obtained; in four cases, the diagnosis of renal car-
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Figure 2 Age distribution at diagnosis of uterine fibroids (red) and reported age distribution at onset of cutaneous leiomyomas (blue)
cinoma was based on pathology reports and/or medical
records.
Renal carcinomas occurred in eight family members
clinically affected with cutaneous leiomyomas and in five
carriers or obligate carriers of an FH germline mutation.
In addition, we identified three relatives who died of kid-
ney cancer, but no slides or pathology reports were avail-
able for review.
Renal tumors were solitary and unilateral. Morpho-
logically, seven renal tumors were classified as papillary
type II renal cell carcinoma, one tumor showed features
suggestive of collecting duct origin, and another was an
unclassified oncocytic tumor. No incipient lesions were
identified in the adjacent normal parenchyma. Cases of
papillary type II renal cell carcinoma displayed a distinct
papillary architecture and characteristic histology (fig. 1).
Cells had an abundant amphophilic cytoplasm and large
nuclei with large inclusion-like eosinophilic nucleoli. The
Furman nuclear grade was 3 or 4 in all cases.
Forty-five individuals with cutaneous leiomyomas had
a CT scan of the abdomen and pelvis followed by ul-
trasound of the kidneys. No evidence of kidney tumors
was present in 84.4% (38/45) of individuals. Renal tu-
mors were present in 15.6% (7/45) of individuals (fig.
1). The size of the renal tumors ranged from 3.8 to 14.5
cm in diameter. The median age at detection of renal
tumors was 44 years. Four individuals who were diag-
nosed with renal tumors at 30 years of age (respec-
tively, 23, 26, 28, and 30 years of age) had an aggressive
disease. Overall, renal cell carcinoma was associated
with an aggressive disease course, with 9 of 13 patients
dead of metastatic disease within 5 years of diagnosis.
Other Evaluations
In our clinical evaluation, we considered but did not
find the phenotypic expression of two other conditions:
FHD, which is an autosomal recessive disease due to mu-
tations in FH, and esophageal leiomyomas. Patients de-
nied neurological symptoms, and a general neurological
examination did not reveal gross neurological abnormali-
ties (e.g., microcephaly, hypotonia, and psychomotor re-
tardation). Leiomyomatosis of the esophagus has been
reported in other inherited syndromes, including multiple
endocrine neoplasia type 1 (McKeeby et al. 2001). The
cohort of patients studied denied substernal pain, dyspha-
gia, or other upper-gastrointestinal symptoms typically
associated with leiomyomas of the esophagus. Screening
CT of the chest in 32 individuals did not show esophageal
lesions suggestive of leiomyomas.
Haplotype Analysis and Mutation Analysis
As an initial step in our investigation, we selected three
families with HLRCC for the genotyping of six polymor-
phic microsatellite markers around the leiomyoma locus,
at 1q42.3-43 (Alam et al. 2001; Launonen et al. 2001).
We constructed haplotypes on the basis of genotyping
results, to identify alleles that were consistently inherited
with cutaneous leiomyomas. Haplotype analysis consis-
tently showed that a haplotype cosegregated with disease
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Figure 3 Physical map of the FH critical region on 1q42.3 A, Ideogram of human chromosome 1q long arm with some markers at
1q42.3-43, with integrated genetic map (above) and physical map (below), showing locations of selected polymorphic markers. Cent. p
centromere; Tel.p telomere. B, Expanded physical map. The BAC tiling path is shown by blue horizontal lines and GenBank clone ID numbers.
BAC overlaps were confirmed in silico. A sequence gap is present in the 2.6-Mb region. C, Locations of known genes, shown within the 2.6-
Mb region of FH. Seven known genes were identified and confirmed by searching public and private databases. D, FH exon-intron structure
and mutations identified in the exonic sequence.
(data not shown).We selected family 214 for linkage anal-
ysis, to confirm linkage to 1q42.3-43. A maximum two-
point LOD score of 2.47 was obtained for D1S517 at
recombination fraction 0 (data not shown). By brows-
ing and searching public and private databases (University
of California–Santa Cruz [UCSC] Genome Bioinformat-
ics, the National Center for Biotechnology Information
[NCBI], Ensembl Genome Browser, and Celera), we con-
structed an integrated genetic and physical map of the
region of nonrecombination (fig. 3).
Sequence analysis of the signal peptide, nine coding
exons, and splice-site junctions of FH revealed muta-
tions in 89% (31/35) of families with HLRCC (fig. 3
and table 1). We found a total of 20 mutations in the
FH coding sequence. Each family’s mutation cosegre-
gated with disease and was absent in 1210 unaffected
individuals. Of these 20 different mutations, 18 were
novel, and 2 (R190H and K187R) have previously been
reported. Of these 20 mutations, 13 missensemutations
were identified; the remaining 7 mutations consisted of
2 insertions and 5 deletions causing frameshifts leading
to premature truncation of the protein (fig. 4). No large
deletions including the FH gene were identified (data
not shown). Eleven unrelated families from diverse eth-
nic backgrounds and regions had the R190H mutation.
Haplotype analysis did not support a founder effect
(data not shown). Therefore, the R190H mutation may
represent a mutational hotspot. In addition, two un-
related families shared the Y422C mutation.
Genotype-Phenotype Correlation
We found mutations in all exons except 1, 2, and 5.
Exon 4 (in 16 families with mutations) and exon 6 (in
8 families with mutations) had the majority of the mu-
tations (fig. 3). Tomlinson et al. (2002) reported that the
location of FH mutations associated with FHD differs
significantly from that associated with leiomyomatosis.
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Table 1
FH Mutations in Families with HLRCC ( )Np 35
Family Exon Mutation Codon Predicted Result
260 3 Gdel @ 288 97rSTOP Frameshift, protein truncation
8413 4 C431T S144L Missense
253 4 A434G N145S Missense
8811 4 T455C M152T Missense
8411 4 A560G K187R Missense
166 4 G569A R190H Missense
252 4 G569A R190H Missense
262 4 G569A R190H Missense
255 4 G569A R190H Missense
257 4 G569A R190H Missense
258 4 G569A R190H Missense
8400 4 G569A R190H Missense
8812 4 G569A R190H Missense
8425 4 G569A R190H Missense
8487 4 G569A R190H Missense
8432 4 G569A R190H Missense
8401 4 G569T R190L Missense
254 6 delGC @ 780 L260rSTOP Frameshift, protein truncation
8518 6 7-bp del @ 782–788 P261rSTOP Frameshift, protein truncation
261 6 C823T H275Y Missense
8424 6 T836A V279D Missense
8517 6 T875C L292P Missense
8423 6 T891A N297D Missense
8428 6 G968A S323N Missense
8808 6 A964G S322G Missense
8810 7 2-bp ins @ 1004 E335rSTOP Frameshift, protein truncation
251 8 delA @ 1162 T388rSTOP Frameshift, protein truncation
259 9 A1265G Y422C Missense
8408 9 A1265G Y422C Missense
8415 9 8-bp dup @ 1300–1307 S437rSTOP Frameshift, protein truncation
6844 9 delG @ 1339 G447rSTOP Frameshift, protein truncation
700 ND ND ND ND
572 ND ND ND ND
501 ND ND ND ND
511 ND ND ND ND
NOTE.—Mutations are named according to the recommendations of the Nomenclature Sys-
tem for Human Gene Mutations. Nucleotide numbering is according to the cytosolic FH
sequence (GenBank accession number NM_000143), with the A of the ATG initiator codon
as nucleotide position 1. Amino acid positions were numbered from the translation of the
cytosolic FH nucleotide sequence. ND p not detected.
They found that mutations in families with leiomyoma-
tosis occurred toward the amino terminus of FH, with
22 of 24 located before codon 250, whereas 8 of the 10
mutations reported to be associated with FHD were lo-
cated after codon 250 ( ). Therefore, a com-P ! .0001
parison of the reported FH mutations associated with
FHD and the FH mutations identified in the present
study was conducted. We found that 17 of 31 FH mu-
tations in the families studied are located before codon
250. In contrast, 8 of the 10 FH mutations reported in
FHD were located after codon 250 ( ).Pp .075
We also compared the location of FHmutations found
in patients with and without renal cancer. Whereas one
family with renal cancer had a mutation before codon
250, four families with renal cancer had mutations after
codon 250 ( ). Two families with renal cancerPp .148
had missense mutations (H275Y and R190L), and three
families with renal cancer had frameshift mutations (an
AA insertion at nucleotide position 1004, resulting in a
stop codon 2 amino acids downstream; an A deletion at
nucleotide position 1162, resulting in a stop codon 16
amino acids downstream; and a G deletion at nucleotide
position 1339, resulting in a stop codon 10 amino acids
downstream) (fig. 4). Four of these five mutations were
associated with papillary type II renal cell carcinoma. The
G deletion at nucleotide position 1339 was identified in
an individual affected with collecting duct carcinoma
(CDC) of the kidney.
All the families with HLRCC except one (family 8401)
included women affected with uterine fibroids. There was
no correlation between the location or type of mutation
and uterine fibroids. In addition, there was no correlation
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Figure 4 FH mutations in patients with HLRCC. Sequencing chromatograms of genomic DNA from control subjects and patients are shown
at left (arrows indicate the position of the identified nucleotide changes), and pedigrees are shown at right (asterisks indicate history of renal cancer).
The delA at nucleotide 1162 (A), a delG at nucleotide 1339 (D), a delGC at nucleotides 780 and 781 (E), and an 8-bp duplication at nucleotides
1300–1307 (F) cause shifts in the reading frame that lead to a stop codon downstream and truncate the corresponding protein; a missense mutation,
G569A (B), changes an arginine to a histidine at codon 190, and another missense mutation, C823T (C), changes a histidine to a tyrosine at codon
275. Sequences containing insertions and deletions are derived from subcloned alleles from affected patients.
between the type of mutation and the severity of disease
in terms of onset, survival, or number of individuals af-
fected (data not shown).
Discussion
We characterized the clinical and genetic features of 35
families with HLRCC in North America. In 89% (31/
35) of the cohort of families studied in North America,
sequence analysis revealed germline mutations in FH. In
contrast, the LeiomyomaConsortium identified germline
mutations in FH in 60% (25/42) of the cohort of Europe-
an families with leiomyomatosis that they studied. We
did not identify mutations in four of the families that
we studied. This may be due to either sequence changes
in introns that affect splicing or single-nucleotide substi-
tutions in the 3′ UTR of FH. We did not find large dele-
tions of the entire FH gene in the cohort of individuals
studied (data not shown). Large deletions including the
entire FH gene, of ∼2.4 and ∼1.9 Mb, were identified
in two English families by use of FISH (Tomlinson et al.
2002). We identified 20 different FHmutations, of which
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18 were novel. Of these 20 mutations, 7 were frameshifts
(2 insertions and 5 deletions) leading to premature trunca-
tion of the protein, and 13 were missense changes predict-
ed to result in substitution of the amino acids.
Of the families with HLRCC that we studied, 55%
(17/31) had FH mutations before codon 250. In con-
trast, the Leiomyoma Consortium found that 92% (22/
24) of mutations associated with HLRCC were located
before codon 250 (Tomlinson et al. 2002). As we con-
tinue to identify additional FH mutations, we expect to
confirm our finding that FH mutations associated with
HLRCC are distributed throughout the gene, rather than
mostly localized to the amino-terminal half of FH.
The distinction between the phenotypic expression of
HLRCC and that of FHD is most likely due to the pat-
tern of inheritance, rather than to the location of the FH
mutation. FHD arises when there is an autosomal reces-
sive inheritance that results in germline biallelic muta-
tions in FH, and it is characterized by severe neurological
impairment, including hypotonia, seizures, and cerebral
atrophy. The deprivation of aerobic energy due to loss
of function of the FH mitochondrial isoenzyme in brain
tissue at early embryogenesis may interfere with normal
fetal brain development. This may explain the neurolog-
ical impairment associated with FHD. Leiomyomas and
renal cancer have not been reported in individuals af-
fected with FHD; however, most individuals with FHD
survive only a few months, and very few survive early
adulthood. Parents (FH-mutation heterozygous) of indi-
viduals affected with FHD have been reported to develop
cutaneous leiomyomas, as present in individuals affected
with HLRCC (Tomlinson et al. 2002). In contrast to
FHD, for HLRCC, germline mutations in FH are inher-
ited in an autosomal dominant pattern, leading to pre-
disposition to the development of uterine and cutaneous
leiomyomas and renal cancer. We also found that the
cohort of patients with HLRCC that we studied did not
develop hypotonia, seizures, or neurological impairment.
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This evidence, in combination with the distribution of
FH mutations associated with HLRCC throughout the
gene, strongly suggests that the pattern of inheritance of
FH mutations determines the phenotypic expression of
disease.
We identified renal cancer in 5 of 35 families. Histo-
logically, papillary renal cell carcinoma constitutes 15%
of all renal cancer (Kovacs et al. 1997). Papillary type
II renal cell carcinoma, an uncommon histologic type
of renal cell cancer, was the predominant type of renal
tumor that occurred in the patients whom we studied.
To our knowledge, only three families with HLRCC
have been described in the renal cancer literature (Kiuru
et al. 2001; Launonen et al. 2001). Germline mutations
in FH have been reported in these three Finnish kindreds
with papillary type II renal cell carcinoma. Two families
shared a 2-base deletion in codon 181, and the other
had the Arg300Xmutation (Tomlinson et al. 2002). The
failure to identify renal tumors in families with leiomyo-
matosis described previously (Alam et al. 2001) may be
due, in part, to the lack of screening for renal tumors
or to the possibility that papillary tumors can be missed
by renal ultrasound (Choyke et al. 1997). In the present
study, we also describe the first reported case of HLRCC
suggestive of CDC of the kidney, with germline muta-
tion in FH. Interestingly, this is consistent with reports,
in the literature, of cytogenetic abnormalities found in
CDC, including monosomy of chromosome 1, as well
as LOH of 1q (reported to occur in 60%–80% of cases)
(Steiner et al. 1996; Fuzesi et al. 1992). Furthermore, the
patient whom we studied had the typical clinical presen-
tation of CDC, which is characterized by an aggressive
disease course with evidence of metastatic disease at the
time of presentation and poor prognosis (Kennedy et al.
1990). Therefore, the present study expands the histo-
logic spectrum of renal tumors in HLRCC.
The biologic characteristics of the renal tumors also
provided support for the concept that HLRCC con-
ferred an inherited predisposition to the development
of renal tumors. Absence or low FH enzyme activity
and loss of the wild-type allele in renal tumors suggest
that FH is involved in the development of renal tumors
(Tomlinson et al. 2002). However, several lines of evi-
dence suggest that modifying genes, environmental fac-
tors, or other tumorigenic mechanisms may play a role
in the development of renal tumors. First, renal tumors
in HLRCC are solitary and unilateral, in contrast to
renal tumors in VHL, HPRC, and BHD, which are usu-
ally multiple and bilateral and for which numerous mi-
croscopic renal-tumor precursors have been observed
within the normal renal parenchyma (Walther et al.
1995; Ornstein et al. 2000; Zbar et al. 2002); further-
more, the lack of multifocal disease in the kidney and
the presence of segmental distribution of skin lesions
suggest the possibility of mosaicism in some affected
individuals with HLRCC. Second, whereas only 10%–
15% of families with HLRCC develop kidney cancer,
80%–90% of families with VHL and HPRC have one
or more individual with kidney cancer. Third, there was
variability of expression of renal tumors both between
and within families; family 214 had the R190H mu-
tation and included four individuals affected with renal
tumors, whereas an additional 10 families who shared
the R190H mutation and were screened for occult renal
tumors lacked individuals affected with renal tumors.
These findings suggest that the existence of other genet-
ic and/or environmental factors may influence the phe-
notype.
The cohort of women with cutaneous leiomyomas
that we studied had a higher prevalence and an earlier
age at diagnosis of uterine fibroids than did women in
the general population. Ninety-eight percent had uterine
fibroids, with a mean age at diagnosis of 30 years. In
the general population, the reported prevalence rates of
uterine fibroids range from 22% to 77%, with the high-
est prevalence in women 40–44 years of age (Marshall
et al. 1997; Stewart et al. 2001). In addition, 89% of
women in the cohort of women with cutaneous leiomy-
omas that we studied had a hysterectomy for symptom-
atic uterine fibroids. Of these, 57% had a hysterectomy
at 30 years of age. In contrast, hysterectomy surveil-
lance in the United States from 1994 to 1999 showed
that hysterectomy was most frequent for those 40–44
years of age, with 52% of women undergoing hyster-
ectomy at 44 years of age (Keshavarz et al. 2002).
The early age at onset of symptomatic uterine fibroids
had a significant impact on the childbearing years of
women with HLRCC.
In conclusion, germline mutations in FH predispose
families in North America to the development of cutane-
ous and uterine leiomyomas and renal cancer. The mech-
anisms by which FH defects promote tumorigenesis are
unknown, but may involve alterations in citrate produc-
tion, activation of hypoxia pathways (including HIF-1),
or free radical formation. In addition to cutaneous leio-
myomas, HLRCC is associated with clinically significant
uterine fibroids and aggressive renal tumors. Screening
for renal tumors is best done with CT scans of the ab-
domen and pelvis. Renal ultrasounds alone are not suf-
ficient, because papillary renal tumors are often isoechoic
and can be missed on ultrasound. A characteristic feature
of many papillary tumors is a lesion that is seen on CT
but may not be detected on ultrasound examination.
HLRCC needs to be considered in the differential diag-
nosis in any patient with renal cancer, ranging from pap-
illary type II renal cell carcinomas to renal tumors with
collecting duct histology that are unilateral and solitary.
It also needs to be considered in the differential diagnosis
of women with a family history of renal cancer and early
onset of multiple uterine fibroids. Appropriate counseling
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is necessary for women, to insure informed reproductive
decisions.
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Appendix A
Supplementary Data
Two-point LOD scores were calculated with Mlink in
Linkage package, version 5.1 (Lathrop et al. 1984), us-
ing the high-penetrance model. Autosomal dominant in-
heritance was assumed, with a gene frequency of 0.0001
and three liability classes. Allele frequencies were esti-
mated on the basis of the genotypes of unrelated spous-
es. Individuals were considered as affected if they had
cutaneous leiomyomas. The genomic and BAC sequenc-
es were derived from available public and private data-
bases (UCSC Genome Bioinformatics, NCBI, Ensembl
Genome Browser, and Celera). The locations of BAC
sequences and the genetic markers on the physical map
were determined by the BLAST 2 (Tatusova and Mad-
den 1999; also see the NCBI BLAST Home Page) and
BLAT (Kent 2002; also see the UCSC Genome Bioin-
formatics Web site) algorithms. A 6.2-Mb region of the
assembled genomic sequence was extracted by using a
distal marker, D1S517, and a proximal marker, D1S423.
The known and predicted genes were identified by
browsing and searching databases (UCSC Genome
Bioinformatics, NCBI, Ensembl Genome Browser, and
Celera). Exon-intron structure of FH was determined
by analysis of the genomic structure, using the Wise2
program. An upstream mitochondrial signal peptide
(termed “exon 0”) was localized by Signal P (Nielsen
et al. 1997). In addition, nine coding exons were iden-
tified. Amplicons were designed to evaluate coding se-
quences and splice junctions. Primers located in neigh-
boring introns 20 bp from the splice junctions were
designed with the aid of Oligo Tech, version 1 (Oligos
Etc & Oligo Therapeutics). Standard PCR conditions
were employed with AmpliTaq (Perkin Elmer) or Taq
polymerases (Invitrogen). PCR components are stan-
dard. PCR products were quantitated by agarose gel
electrophoresis and were purified using Multiscreen
PCR cleanup plates (Millipore).
Double-stranded sequencing reactions (10 ml) us-
ing Big Dye Terminators ready reaction mix (Applied
Biosystems) were purified using Performa plates (Edge
Biosystems) and were electrophoresed on an ABI 3700
genetic analyzer. Chromatograms were aligned and an-
alyzed using Lasergene (DNAStar). Alignments were
examined using the conflict finder, to locate Phred-
identified discrepancies; then, forward and reverse
chromatograms from each affected patient were man-
ually examined, to locate additional secondary peaks.
Sequence variants found in one or more affected pa-
tients (but not in unaffected individuals) were exam-
ined for cosegregation with disease in their respective
families by denaturing high-performance liquid chro-
matography (DHPLC) or single-stranded sequencing.
Insertions and deletions were subcloned with a Topo
Cloning Kit (Invitrogen) and were sequenced. A mini-
mum of 210 normal individuals (420 chromosomes)
were examined for the presence of each disease-associ-
ated sequence variant. DHPLC was performed using
a Transgenomic Wave system with a DNASep column.
Temperature predictions were obtained by the Stan-
ford Melt algorithm (see the DHPLC Melt Program
Web site) or Wavemaker (Transgenomic).
Electronic-Database Information




Ensembl Genome Browser, http://www.ensembl.org/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for mito-
chondrial FH precursor cDNA [accession number U59309]
and BAC genomic sequences [accession numbers AL359764
and AL591898])
National Center for Biotechnology Information, http://www
.ncbi.nlm.nih.gov/
NCBI Blast Home Page, http://www.ncbi.nlm.nih.gov/BLAST/
(for BLAST 2)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for multiple cutaneous leiomyo-
matosis, HLRCC, and FHD)
UCSC Genome Bioinformatics, http://genome.ucsc.edu/ (for
Genome Browser and BLAT)
Wise2, http://www.ebi.ac.uk/Wise2/
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